Retatrutide (LY3437943) is an investigational triple-hormone receptor agonist developed by Eli Lilly that targets the GIP, GLP-1, and glucagon receptors simultaneously
The higher the dose , the more pronounced the gastric emptying delay, and the more likely sulfur burps become
When to Talk to a Doctor Seek medical advice if you experience: Persistent or severe nausea Ongoing vomiting Signs of dehydration Severe abdominal pain Unusual or worsening symptoms Your healthcare provider can adjust your dose or provide additional support
More comprehensive insight into the effects of GLP-1 RAs on gastrointestinal and central nervous system functions is required
MBX 4291, dual GLP-1/GIP co-agonist prodrug designed for potential once-monthly dosing and improved tolerability in obesity Recent Highlights: In June 2026, MBX Biosciences announced data that demonstrated sustained benefit of its once-weekly Canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism
Those are FDA-approved medications proven to mimic the GLP-1 hormone and are prescribed for obesity or diabetes
